MAD MONEY FEATURES
Watch the Lightning Round whenever and wherever you want.
Grab this all-in-one application and get recaps of the show sent right to your desktop or blog.
Admit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
Check out Cramer on set, back to school, behind the scenes and more.
Buy Cramer books, bobbleheads and other Mad Money merchandise.
Pick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
Mad Money's mobile. Get show highlights sent to your phone.
Cramer continued with his "Cramerican Marine Field Guide to Recessions" reflecting on the 1990 Playbook (the last time we had a financial meltdown) where healthcare stocks, especially biotech were the winners then, and in Cramer's view are likely to do it again.
Jim named Genentech [DNA
Loading...
()
] as a specific BUY opportunity.
JULY 7TH RECAP
- Sudden Death: Bearish on Boeing, Visa, and Navios Maritime
- Mad Mail: Have Fertilizer Stock Prices Bottomed?
- Natural Gas: Super Hot or Overheated?
- Lightning Round OT: SunPower and Solar Are Overheated
- Focus on the Buying Habits of the Big Money Players
- Lightning Round: Stay Out of Financials
- Win With Genentech Against the Bears
- How to Play the Recession Game
- Stop Trading: Jerry Yang Is On My Wall of Shame
What does Cramer find attractive about Genentech?
- Recent negativity in the media (New York Times) about how expensive Genentech’s drugs are should be seen as a chance to get in on this one at a much lower entry point than you otherwise would’ve been able to.
- Biotech coming into style in the Wall Street fashion show
- Recessions don’t generally stop people from paying for—or having their insurance companies pay for—cancer drugs that will keep them alive for months longer than they ordinarily would.
- For the last three quarters, sales of Avastin have been sluggish, but now it looks like prescription data on Avastin for this quarter is on track to exceed consensus estimates, giving the street a reason to feel good about buying Genentech when it reports after the close on July 14th.
- The Legion of Phase 3 studies expected to come out between now and the end of the year.
How high does Cramer feel Genentech could go?
Cramer said, "I wouldn’t be surprised to see this $76 stock go to $88 or even much, much higher, considering the 1990 playbook where biotech was the best performing group when the financials collapsed."
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?

